Skip to NavigationSkip to content

Bristol-Myers Squibb

Positive CHMP opinion for BMS and Acceleron's Reblozyl in transfusion-dependent anaemia sub-populations

Bristol Myers Squibb and Acceleron Pharma’s Reblozyl (luspatercept) has secured a positivr opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for use in the treatment of transfusion-dependent anaemia in two adult patient populations.

FDA approves BMS' Zeposia in relapsing multiple sclerosis, but COVID-19 will delay its market entry

Image Credit: A4

Bristol-Myers Squibb has secured approval with the FDA for Zeposia (ozanimod) 0.92mg in relapsing forms of multiple sclerosis (RMS), but confirmed the drug wouldn’t be racing to market, as is usually the case.

COVID-19: Gilead freezes compassionate access to remdesivir due to "overwhelming demand", BMS and Lilly delay new study launches

As national governments continue to ramp up measures to contain the ongoing COVID-19 coronavirus outbreak, so too are pharma and biotech organisations in the race to find a working treatment for the disease.  

Gilead has emerged at the front of the pack with its antiviral therapy remdesivir, which is currently proceeding through two late-stage clinical trials. But as a result of tentative success the drug has shown, the company has said it is facing “overwhelming demand” of compassionate use requests to receive the treatment.

Opdivo + cabiralizumab combo falls flat in advanced pancreatic cancer

Five Prime Therapeutics and Bristol-Myers Squibb have confirmed that their randomised Phase 2 trial investigating the efficacy of the former’s cabiralizumab combined with the latter’s blockbuster immunotherapy Opdivo (nivolumab) in the treatment of advanced pancreatic cancer failed to meet its primary endpoint.

The combo fell short both with and without chemotherapy in a study of around 160 enrolled participants with locally advanced or metastatic or locally advanced or metastatic pancreatic cancer that had progressed despite having received one line of chemotherapy.  

Bristol-Myers Squibb drug boasts strong overall survival in acute myeloid leukaemia

Bristol-Myers Squibb took the opportunity at the 2019 American Society of Hematology (ASH) Annual Meeting to reveal new efficacy data on its candidate CC-486 in the maintenance treatment of front-line, newly diagnosed acute myeloid leukaemia (AML) in patients who have achieved remission with intensive induction chemotherapy.

The drug was tested in 472 patients at least 55 years old with de novo or secondary AML with intermediate or poor-risk cytogenetics who had achieved their first complete remission (CR) or complete remission with incomplete count recovery (CRi) after receiving i

Keytruda overtakes Opdivo to lead sales in global immune checkpoint inhibitor market, report reveals

MSD’s Keytruda (pembrolizumab) overtook Bristol-Myers Squibb’s (BMS) blockbuster drug Opdivo (nivolumab) in total sales in the third quarter of 2019 to emerge as leader in the global immune checkpoint inhibitor market, according to a new report from GlobalData.

According to the findings, MSD’s drug saw a 62% growth in revenue compared to Q3 2018 to reach $3.1 million. Over the same period, Opdivo experienced sales growth of just 1%, generating $1.8 million

BMS' Opdivo+Yervoy+Chemo combo shows superior overall survival in first-line lung cancer

Bristol Myers Squibb has lifted the curtain on new Phase 3 data for its blockbuster immunotherapy Opdivo (nivolumab), showing that the drug, when combined with Yervoy (ipilimumab) and two cycles of chemotherapy, met its primary endpoint for the first-line treatment of advanced non-small cell lung cancer (NSCLC).

At a pre-specified analysis, the results illustrated that the combo showed superior overall survival benefit in relation to its comparator, chemotherapy monotherapy for up to four cycles followed by optional maintenance therapy.

BMS' Opdivo bests chemotherapy in oesophageal squamous cell carcinoma

Bristol-Myers Squibb took the opportunity at the European Society for Medical Oncology (ESMO) 2019 Annual Congress to present new Phase 3 data on its blockbuster immunotherapy Opdivo (nivolumab) in the treatment of unresectable advanced or recurrent oesophageal squamous cell carcinoma (ESCC) refractory or intolerant to combination therapy with fluoropyrimidine and platinum-based drugs.

Opdivo was shown to extend overall survival by 23% compared to docetaxel or paclitaxel chemotherapy, meeting the trial’s primary endpoint.

EMA's CHMP recommends new dosing schedule for Opdivo in melanoma

Bristol-Myers Squibb has revealed that its blockbuster immunotherapy drug Opdivo (nivolumab) has secured recommendation from the EMA’s Committee for Medicinal Products for Human Use (CHMP) for a new dosing schedule in the adjuvant treatment of specific patients with melanoma.

The recommendation concerns adult patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection.

BMS unveils strong five-year efficacy data for Opdivo in lung cancer

Bristol-Myers Squibb has unveiled pooled five-year efficacy and safety results for its blockbuster immunotherapy Opdivo (nivolumab) drawn from two Phase 3 studies in the treatment of previously treated advanced non-small cell lung cancer (NSCLC).

BMS’ immunotherapy demonstrated overall survival rates of 13.4% across all patient subgroups after five years of treatment, compared to just 2.6% with docetaxel.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches